Your browser does not support the NLM PubReader view.

Go to this page to see a list of supporting browsers.
The Ewha Medical Journal
Ewha Womans University School of Medicine

Ewha Med J 1993; 16(4):337-340

pISSN: 1598-7450

DOI: https://doi.org/10.12771/emj.1993.16.4.337

Original Article

Phase II Study of Ifosfamide, Etoposide and Cisplatin(IEP) Chemotherapy for Advanced Non-Small Cell Lung Cancer

Soon Nam Lee

Copyright ⓒ 1993. Ewha Womans University School of Medicine. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Published Online: Jul 24, 2015

Abstract

To evaluste the efficacy and toxicity of IEP chemotherapy in locally advanced and metastatic non-small cell lung cancer, nineteen previously untreated patients with non-small cell lung cancer were studied.

Patients received ifosfamide 1000mg/m2 with mesna, 20% of ifosfamide dose at 0,4, 8 hours after ifosfamide, etoposide 100mg/m2, and cisplatin 20mg/m2 with full hydration and mannitol diuresis intravenously on days 1-3 every 4 weeks.

Eighteen male and one female, two stage IIIA, 10 stage IIIB and 7 stage IV patients have been treated.

The response rate of IEP was 26% with no complete remission, 53% of stable disease, and 23% of progressive diasease.

The overall median survival was not reaced yet and 20 month survival rate was 51.4%, The duration of remission was at the range of 4+ to 40 weeks.

The toxicities were alopecia(100%), nausea and vomiting(47%), leukopenia(14%), infection(6%), renal dysfunction(6%) and oral mucositis(5%).

This phase II study of IEP in advanced non-small cell lung cancer is not superior to another combination regimens in terms of response but toxicity was tolerable. Other new chemotherapeutic drugs and newer trials should be developed further.